Investor Relations

Financial Releases

Date Title and Summary Additional Formats
Toggle Summary Intersect ENT to Present at the 34th Annual J.P. Morgan Healthcare Conference
MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (Nasdaq: XENT ), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced that management will present an overview of the company's business, including certain preliminary 2015
View HTML
Toggle Summary Intersect ENT to Present at Piper Jaffray Conference
MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (Nasdaq:XENT) today announced that management will present an overview of the company's business at the 27 th Annual Piper Jaffray Healthcare Conference . The presentation at the Piper Jaffray conference is scheduled for 9:30 a.m.
View HTML
Toggle Summary Intersect ENT Reports Third Quarter 2015 Results
Revenue Increased 56% Year over Year and Gross Margin at 80% MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT , Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the third quarter
View HTML
Toggle Summary Intersect ENT to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum
MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (Nasdaq:XENT) today announced that management will present an overview of the company's business at the 9 th Annual Canaccord Genuity Medical Technology and Diagnostics Forum . The presentation at the Canaccord Genuity forum is scheduled
View HTML
Toggle Summary Intersect ENT to Announce Third Quarter Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ: XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that it will release its third quarter financial results on November 4, 2015 .
View HTML
Toggle Summary Intersect ENT Reports Second Quarter 2015 Results
Revenue Increased 77% Year Over Year to $15.2 Million and Gross Margins Rise to 81% MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT , Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for
View HTML
Toggle Summary Intersect ENT to Present at the Wedbush PacGrow Life Sciences and Canaccord Genuity Conferences
MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (Nasdaq: XENT) today announced that management will present an overview of the company's business at the Wedbush PacGrow Life Sciences 2015 Life Sciences Management Access Conference and at the Canaccord Genuity 2015 Growth Conference.
View HTML
Toggle Summary Intersect ENT to Announce Second Quarter Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ:XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that it will release its second quarter financial results on August 5, 2015 .
View HTML
Toggle Summary Intersect ENT to Present at Cantor Fitzgerald's Inaugural Healthcare Conference
MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ:XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that management will present an overview of the company's business at Cantor Fitzgerald's Healthcare
View HTML
Toggle Summary Intersect ENT Announces Exercise of Underwriters' Option and the Closing of Its Public Offering
Underwriters Exercise Option for 537,300 Shares of Common Stock, Increasing Total Aggregate Proceeds to Approximately $103.0 Million MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT , Inc. (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and
View HTML